APIC – Active Pharmaceutical Ingredients Committee


APIC represents producers of APIs and API intermediates in Europe.

Its membership consists of 60 companies, located all over Europe, and of 4 national industry associations.

For around 2/3 of its members, selling APIs and intermediates is their major business while ca. 1/3 of the members are primarily marketing final medicinal products. APIC’s focus is on worldwide Quality, Good Manufacturing Practice (GMP) and Regulatory matters relating to APIs and intermediates.

 

CHAIR
H. Vanneste (Janssen Pharmaceutica NV)

 

SUBSTANCES
Active pharmaceutical ingredients

 

MEMBERSHIP

  1. Abbvie IE
  2. Ajinomoto Bio-Pharma Services (BE)
  3. Ardena OSS B.V (NL)
  4. Aspen Oss B.V. (NL)
  5. Bachem SA (CH)
  6. BASF (DE + NO)
  7. Biospring (DE)
  8. Boehringer Ingelheim Pharma KG (DE)
  9. Bracco Suisse SA (CH)
  10. Cabot Norit Nederland BV (NL)
  11. Cambrex Karlskoga AB (SE)
  12. CARBOGEN AMCIS (CH)
  13. Cargill NV (BE & IT)
  14. Centrient Pharmaceuticals (NL, ES)
  15. CIPAN SA (PT)
  16. Corbion (NL)
  17. CordenPharma International GmbH (DE)
  18. Dipharma Francis Srl (IT)
  19. DOW Europe GmbH (CH)
  20. DSM Nutritional Products (CH)
  21. EGIS Pharmaceuticals (HU)
  22. Esteve Healthcare SL (ES)
  23. Euroapi (FR)
  24. Evonik (DE, FR)
  25. Excella GmbH (DE)
  26. Farmhispania SA (ES)
  27. F.I.S. SpA (IT)
  28. GE Healthcare AS (NO)
  29. Grace & Co (DE + US) – Albemarle
  30. Hovione FarmaCiencia SA (PT)
  31. IFF (DuPont Nutrition & Biosciences) (NL)
  32. Johnson & Johnson Innovative Medicine (BE)
  33. Jungbunzlauer Ladenburg (DE)
  34. K+S Minerals GmbH (DE)
  35. Lesaffre (FR)
  36. Lonza AG (CH)
  37. Macfarlan Smith Ltd (UK)
  38. Medichem SA (ES)
  39. Merck & Company (MSD)
  40. Merck KGaA (DE)
  41. Minakem (BE + FR) (Minafin)
  42. Novo Nordisk A/S (FEF Chemicals) (DK)
  43. Ofichem BV (NL)
  44. Olon SpA (IT)
  45. Orion Corporation, Fermion Oy (FI)
  46. Patheon Austria GmbH (AT)
  47. Pfizer Inc. (BE)
  48. Pharmaron Manufacturing Services (UK)
  49. PolyPeptide Laboratories AB (SE)
  50. Purac Biochem B.V. (Corbion) (NL)
  51. Roquette Frères SA (FR)
  52. Sandoz (DE + SI) (Lek)
  53. Seqens (CU Chemie,Novacyl, PCAS) (FR) DE)
  54. Seratec (FR)
  55. Siegfried AG Ltd (CH)
  56. Specialty Electronic Materials Belgium (DuPont) (BE+FR+NL)
  57. Sterling Pharma Solutions Ltd (UK)
  58. Swords Labs Ltd (BristolMyers) (IE)
  59. Symrise AG (DE)
  60. Synthon bv (NL)
  61. Takeda (Baxter) (AT)
  62. Tereos (FR)
  63. Teva Pharmaceuticals Ind. Ltd (IL,IT,HU)
  64. Uquifa SA (ES)
  65. Vistin Pharma AS (NO)
  66. Xellia Pharmaceuticals ApS (DK, NO)
  67. Zentiva k.s. (CZ)

National Federations:

AFAQUIM (ES)
Aschimfarma (Federchimica) (IT)
BioPharmaChem Ireland (IE)
SICOS Biochimie (FR)

 

Partners:

ABIFINA (Brazil)
BPTF (US)
BDMA  (India)                                                      
JAPTA  (Japan)  
KPTA    (Korea)                                                                                  

 

OBJECTIVES
Networking/ Advocacy: to continually improve our contacts and to increase the profile of APIC with all relevant stakeholders.
Level Playing Field: to strongly advocate regulatory compliance in all global markets and its enforcement through inspection.
Post approval change authorisation: to put the responsibility to manage change into the hands of industry.
Harmonisation: to support global harmonisation in the fields of quality and regulatory affairs.

 

ORGANISATION CHART

For more information:
http://apic.cefic.org/

TEAM

Sector Group Manager

Pieter van der Hoeven
+32.475.270.571
pvd@cefic.be

Assistant

Anais Fantasia

+32.496.268.162

afa@cefic.be